SLC5A2 and type 2 diabetes mellitus: Large randomized controlled trials on SGLT2 inhibitors in T2DM have shown remarkable benefits on cardiovascular and renal outcomes in individuals with established ASCVDs.15, 16, 17, 18, 19, 20, 21, 22